Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
— YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year1, and achieved record brand profitability — Open-label portion of the pivotal Phase 3 CYPRESS study ofampreloxetine now complete; topline readout on track for Q1 2026 — Company to host anampreloxetine focused virtual Key Opinion Leader (KOL) event for […]